---

RESULTS FOR THE YEAR ENDED 31ST MARCH, 2012

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2012

						(Rupees in '000')
			Un -audited			Audited
S. No.	Particulars		Quarter ended			Year Ended	Year Ended
			31.03.2012	31.12.2011	31.03.2011	31.03.2012	31.03.2011
PART-I
1	(a) Income from Operation
		Gross Sales	13,225	17,496	10,838	70,455	60,337
		Less: Excise Duty	1,509	1,000	1,156	4,435	3,313
	Net Sales		11,716	16,496	9,682	66,020	57,024
	(b) Other Operating Income		-	-	-	-	-
	Total Income from Operation		11,716	16,496	9,682	66,020	57,024
2	Expenditure		-	-	-	-	-
	(a)	Consumption of Materials	6,761	4,587	3,754	24,418	21,033
	(b)	Purchase of Goods Traded	937	483	-	3,457	3,045
	(c)	(Increase)/Decrease in stock in trade	-5,021	1,473	-2,133	-1,095	-2,311
	(d)	Staff Cost	4,610	6,314	4,175	22,545	19,048
	(e)	Depreciation	666	644	650	2,599	2,578
	(f)	Other Expenditure	3,292	2,329	2,679	11,694	11,507
	Total Expenditure		11,245	15,830	9,125	63,618	54,900
3	Profit/Loss from Operation Before Other Income (1-2)		471	666	557	2,402	2,124
4	Other Income/(Loss)		159	55	45	369	222
5	Profit/Loss before Interest & Exceptional items (3+4)		630	721	602	2,771	2,346
6	Interest		569	526	395	1,893	1,561
7	Profit/Loss after Interest but before exceptional items (5-6)		61	195	207	878	785
8	Exceptional items		-	-	-	-	-
9	Profit/Loss before Tax (7-8)		61	195	207	878	785
10	Tax Expenses (Provision for Taxation):      Current tax		-	-	-	158	134
		Deffered tax	-	-	-	-384	-78
11	Net Profit/Loss after Tax (9-10)		61	195	207	1,104	729
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35	354,35
	[Net of allotment money in arrears]
13	Reserves Excluding Revaluation Reserves		-	-	-	7,630	6,526
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-	-
	Basic & Diluted		-	-	-	0.24	0.16
PART-II	A. PARTICULARS  OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	29,02,900	29,02,900	29,02,900	29,02,900	29,02,900
	ii)	Percentage of shareholding	63.51%	63.51%	63.51%	63.51%	63.51%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	1668100	1668100	1668100	1668100	1668100
	ii)	Percentage of shares (as a% of the total shareholding	36.49%	36.49%	36.49%	36.49%	36.49%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%	100%
	B. INVESTORS COMPLAINTS		3 Months ended 31.03.2012
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

 

STATEMENT OF ASSETS AND LIAB ILITIES						(Rupees in '000')
Particulars						As at 31.03.2012	As at 31.03.2011
						(Audited)	(Audited)
A		EQUITY AND LIABILITIES
1		SHARE HOLDERS FUND
	a)	Share Capital				35,435	35,435
	b)	Reserves and Surplus				26,350	24,846
		Sub-Total of Shareholders Fund				61,785	60,281
2		NON CURRENT LIABILITIES
	a)	Long term borrowing				23,918	28,467
	b)	Deffered tax liability( net)				3,100	3,484
	c)	Other  long term liability				98	75
	d)	Long term Provision				-	-
		Sub-Total of Non Current Liabilities				27,116	32,026
3		CURRENT LIABILITIES
	a)	Short term borrowing				-	-
	b)	Trade payable				9,217	6,630
	c)	Other current liabilities				4,057	3,037
	d)	Short term provision				-	-
		Sub-Total of Current Liabilities				13,274	9,667
		Total ( 1+2+3)				1,02,175	1,01,974
B		ASSETS
1		NON CURRENT ASSETS
	a)	Fixed Assets				42,361	44,131
	b)	Non current investments				3,159	3,159
	c)	Long term loans and advances				13,763	13,959
	d)	Other Non current assets				525	-
		Sub-Total of Non Current Assets				59,808	61,249
2		CURRENT ASSETS
	a)	Inventories				21,333	19,028
	b)	Trade receivable				10,843	9,232
	c)	Cash and cash equivalents				9,258	11,714
	d)	Short term loans and advances				933	751
		Sub-Total of  Current Assets				42,367	40,725
		Total ( 1+2 )				1,02,175	1,01,974

 

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on  31.05.2012 The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable. Previous period figures  have been regrouped wherever  required.

 

	For and on behalf of the Board
	COLINZ LABORATORIES LIMITED
Mumbai	Dr. L. S. Mani
31.05.2012	Chairman & Managing Director.

 

(Top)